JP2023551519A - 抗ｃｄ１９抗体とパルサクリシブの組み合わせ療法 - Google Patents

抗ｃｄ１９抗体とパルサクリシブの組み合わせ療法 Download PDF

Info

Publication number
JP2023551519A
JP2023551519A JP2023532759A JP2023532759A JP2023551519A JP 2023551519 A JP2023551519 A JP 2023551519A JP 2023532759 A JP2023532759 A JP 2023532759A JP 2023532759 A JP2023532759 A JP 2023532759A JP 2023551519 A JP2023551519 A JP 2023551519A
Authority
JP
Japan
Prior art keywords
lymphoma
dose
antibody
days
hodgkin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023532759A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023551519A5 (https=
Inventor
ラングミュア，ピーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2021/012982 external-priority patent/WO2022115120A1/en
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of JP2023551519A publication Critical patent/JP2023551519A/ja
Publication of JP2023551519A5 publication Critical patent/JP2023551519A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023532759A 2020-11-30 2021-11-30 抗ｃｄ１９抗体とパルサクリシブの組み合わせ療法 Pending JP2023551519A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063119370P 2020-11-30 2020-11-30
US63/119,370 2020-11-30
PCT/US2021/012982 WO2022115120A1 (en) 2020-11-30 2021-01-11 Combination therapy with an anti-cd19 antibody and parsaclisib
USPCT/US2021/012982 2021-01-11
PCT/US2021/061145 WO2022115762A1 (en) 2020-11-30 2021-11-30 Combination therapy with an anti-cd19 antibody and parsaclisib

Publications (2)

Publication Number Publication Date
JP2023551519A true JP2023551519A (ja) 2023-12-08
JP2023551519A5 JP2023551519A5 (https=) 2024-11-29

Family

ID=79021728

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023532759A Pending JP2023551519A (ja) 2020-11-30 2021-11-30 抗ｃｄ１９抗体とパルサクリシブの組み合わせ療法

Country Status (6)

Country Link
US (2) US20220241411A1 (https=)
EP (1) EP4251138A1 (https=)
JP (1) JP2023551519A (https=)
CA (1) CA3203587A1 (https=)
TW (1) TW202241436A (https=)
WO (1) WO2022115762A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2767063C2 (ru) 2015-08-21 2022-03-16 МорфоСис АГ Комбинации и их использование

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018523685A (ja) * 2015-08-21 2018-08-23 モルフォシス・アーゲー 組み合わせおよびその使用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
KR100786927B1 (ko) 2000-06-28 2007-12-17 스미스클라인비이참피이엘시이 습식 분쇄방법
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
WO2004072266A2 (en) 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
PT3513793T (pt) 2011-09-02 2021-05-10 Incyte Holdings Corp Heterociclilaminas como inibidores de pi3k
TWI687220B (zh) 2013-03-01 2020-03-11 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
SG10201907576SA (en) 2015-02-27 2019-09-27 Incyte Corp Salts of pi3k inhibitor and processes for their preparation
LT3302550T (lt) * 2015-05-26 2019-11-11 Morphosys Ag Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas
LT3630177T (lt) * 2017-05-31 2023-10-25 Morphosys Ag Gydymo paradigma, skirta kompleksiniam gydymui anti-cd19 antikūnu ir venetoklaksu

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018523685A (ja) * 2015-08-21 2018-08-23 モルフォシス・アーゲー 組み合わせおよびその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 133, no. 16, JPN6025048854, 2019, pages 1742 - 1752, ISSN: 0005743882 *

Also Published As

Publication number Publication date
US20250090659A1 (en) 2025-03-20
TW202241436A (zh) 2022-11-01
WO2022115762A1 (en) 2022-06-02
US20220241411A1 (en) 2022-08-04
CA3203587A1 (en) 2022-06-02
EP4251138A1 (en) 2023-10-04

Similar Documents

Publication Publication Date Title
TWI835808B (zh) 抗pd-1抗體及其用途
CN119679936A (zh) 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法
JP2022543062A (ja) Ｉｄｏ阻害剤の投与レジメン
TW201600527A (zh) 結合人類大麻素１（ｃｂ１）受體之抗體
US20250228936A1 (en) Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
CN118317975A (zh) 靶向baff-r的抗体及其用途
US20260062483A1 (en) Treatment paradigm for an anti-cd19 antibody therapy
JP7212138B2 (ja) 抗ｃｄ４０抗体及びその使用
BR112018006633A2 (en) antibodies that bind to human cannabinoid receptor 1 (cb1)
US20250090659A1 (en) Combination therapy with an anti-cd19 antibody and parsaclisib
WO2025134049A1 (en) Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis
CN117794522A (zh) 抗cd19抗体和帕萨昔布的组合疗法
WO2022115120A1 (en) Combination therapy with an anti-cd19 antibody and parsaclisib
US20260102490A1 (en) Combination of trispecific antibody targeting bcma, gprc5d and cd3, and an anti-cd38 antibody for the treatment of multiple myeloma
TWI915345B (zh) 包含axl/mer及pd-1/pd-l1抑制劑之組合療法
US20250129174A1 (en) Anti-4-1-1bbxccr8 antibodies and uses thereof
US20250325664A1 (en) Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibitor
WO2026078647A1 (en) Combination of trispecific antibody targeting bcma, gprc5d and cd3, and pomalidomide for the treatment of multiple myeloma
WO2025130990A1 (zh) 肿瘤微环境激活的药物偶联物及抗体药物偶联物
EA050986B1 (ru) Комбинированная терапия, включающая ингибиторы axl/mer и pd-1/pd-l1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241121

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260227